Long-Term Treatment With Ocrelizumab in Patients With Early-Stage Relapsing MS

Jahr

2025

Autoren

Cerqueira JJ, Berthele A, Cree BAC, Filippi M, Pardo G, Pearson OR, Traboulsee A, Ziemssen T, Vollmer T, Bernasconi C, Mandel CR, Kulyk I, Chognot C, Raposo C, Schneble HM, Thanei GA, Incera E, Havrdová EK.

Verlag

Neurology. 2025 Feb 25;104(4):e210142.

Link

https://doi.org/10.1212/WNL.0000000000210142

Long-Term Treatment With Ocrelizumab in Patients With Early-Stage Relapsing MS

Digital Representation of Patients as Medical Digital Twins: Data-Centric Viewpoint

A plain language summary of a study exploring the experiences of people with relapsing–remitting multiple sclerosis: what symptoms and impacts of the disease matter most and how can they be evaluated better?

Cost–consequence analysis of early vs. delayed natalizumab use in highly active relapsing–remitting multiple sclerosis: a simulation study

RENEWED: A follow-up study of the opicinumab phase 2 RENEW study in participants with acute optic neuritis

Funktionelle Elektrostimulation zur Versorgung bei paretischen Gangstörungen: Fokus auf Fußheberschwäche bei Multipler Sklerose